William Wood, MD, and colleagues presented preliminary findings at the American Society of Hematology Annual Meeting that found multiple myeloma patients seen at an NCI comprehensive cancer center within one year of diagnosis had better survival, even after controlling for various factors.
Researchers led by UNC Lineberger’s Joshua Zeidner, MD, presented preliminary results from an ongoing phase II trial of the checkpoint inhibitor pembrolizumab and chemotherapy for relapsed or refractory acute myeloid leukemia at the 59th American Society of Hematology Annual Meeting in Atlanta.
The biological features of patients’ tumors partially explained a racial disparity for women with hormone receptor-positive, HER2-negative breast cancer, but UNC Lineberger researchers led by Katherine Reeder-Hayes, MD, MBA, MSc, said it didn’t explain it completely. The preliminary findings were reported at the 2017 San Antonio Breast Cancer Symposium.
A desire to give back has led breast cancer survivor Regina Jones to volunteer at the N.C. Cancer Hospital, UNC Lineberger’s clinical home. Jones is a member of the Patient & Family Advisory Council, or PFAC, which is composed of patients, family members, survivors, caregivers and staff who work together to ensure that patients receive the highest level of care.